A phase iii, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder

Urology

Volumn 82, Issue 2, 2013, Pages 313-320

  Herschorn, Sender ^a   Barkin, Jack ^a   Castro Diaz, David ^b   Frankel, Jeffrey M ^c   Espuna Pons, Montserrat ^d   Gousse, Angelo E ^e   Stölzel, Matthias ^f   Martin, Nancy ^g   Gunther, Adrie ^f   Van Kerrebroeck, Philip ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c Seattle Urological Associates   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f Astellas Pharma Global Development   (Netherlands)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIRABEGRON; PLACEBO;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STRESS INCONTINENCE; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VISUAL ANALOG SCALE; XEROSTOMIA;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TACHYCARDIA; THIAZOLES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 84880919880     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.02.077     Document Type: Article

References (22)

1. P. Abrams, and K.E. Andersson Muscarinic receptor antagonists for overactive bladder BJU Int 100 2007 987 1006
2. A.O. D'Souza, M.J. Smith, and L.A. Miller Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 2008 291 301
3. J.S. Benner, M.B. Nichol, and E.S. Rovner Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 2010 1276 1282
4. 3-adrenoceptor agonist, on bladder function J Pharmacol Exp Ther 321 2007 642 647
5. T. Takasu Disease concept of the slow virus infection Nihon Rinsho 65 2007 1361 1368
6. V. Nitti, S. Auerbach, and N. Martin Results of a randomized phase III trial of mirabegron in patients with overactive bladder J Urol 189 2013 1388 1395
7. V. Khullar, G. Amarenco, and J. Angulo Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 283 295
8. National Institutes of Health and Blood Institute: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Edited by N. H. L 2004.
9. L. Cardozo, M. Lisec, and R. Millard Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 2004 1919 1924
10. C.R. Chapple, T. Rechberger, and S. Al-Shukri Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 2004 303 310
11. F. Haab, L. Cardozo, and C. Chapple Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome Eur Urol 47 2005 376 384
12. R.A. Appell Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 1997 90 96
13. C. Chapple, W. Steers, and P. Norton A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder BJU Int 95 2005 993 1001
14. F. Haab, L. Stewart, and P. Dwyer Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder Eur Urol 45 2004 420 429
15. S. Hill, V. Khullar, and J.J. Wyndaele Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study Int Urogynecol J Pelvic Floor Dysfunct 17 2006 239 247
16. W. Steers, J. Corcos, and J. Foote An investigation of dose titration with darifenacin, an M3-selective receptor antagonist BJU Int 95 2005 580 586
17. V.W. Nitti, R. Dmochowski, and P.K. Sand Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome J Urol 178 2007 2488 2494
18. C.R. Chapple, S.A. Kaplan, and D. Mitcheson Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder Eur Urol 63 2013 296 305
19. A.J. Wein, and E.S. Rovner Definition and epidemiology of overactive bladder Urology 60 2002 7 12
20. L.D. Cardozo, P.E. Van Kerrebroeck, and D.R. Staskin Considerations for the management of urgency symptoms in patients with overactive bladder syndrome World J Urol 27 2009 755 763
21. C.R. Chapple, W. Artibani, and L.D. Cardozo The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects BJU Int 95 2005 335 340
22. T.H. Wagner, T.W. Hu, and J. Bentkover Health-related consequences of overactive bladder Am J Manag Care 8 2002 S598 S607